Thiazolidinedione inhibits the production of monocyte chemoattractant protein-1 in cytokine-treated human vascular endothelial cells

FEBS Lett. 1999 Jul 2;454(1-2):27-30. doi: 10.1016/s0014-5793(99)00765-6.


The chemokine monocyte chemoattractant protein-1 is a potent chemoattractant for monocytes. Monocyte chemoattractant protein-1 is produced by vascular endothelial cells during inflammatory diseases such as atherosclerosis. In this study, we examined the effects of a thiazolidinedione on monocyte chemoattractant protein-1 expression in human vascular endothelial cells. In human vascular endothelial cells, interleukin-1beta and tumor necrosis factor-alpha induced endogenous monocyte chemoattractant protein-1 protein secretion, mRNA expression and promoter activity. The thiazolidinedione inhibited these effects. In summary, our results indicated that the suppression of the expression of monocyte chemoattractant protein-1 can be accomplished by thiazolidinedione treatment, raising the possibility that thiazolidinedione may be of therapeutic value in the treatment of diseases such as atherosclerosis.

MeSH terms

  • Chemokine CCL2 / antagonists & inhibitors
  • Chemokine CCL2 / biosynthesis*
  • Cytokines / pharmacology*
  • Dose-Response Relationship, Drug
  • Endothelium, Vascular / drug effects*
  • Endothelium, Vascular / metabolism
  • Humans
  • Interleukin-1 / pharmacology
  • Promoter Regions, Genetic
  • Pyrimidines / pharmacology
  • Thiazoles / pharmacology*
  • Thiazolidinediones*
  • Time Factors
  • Tumor Necrosis Factor-alpha / pharmacology


  • Chemokine CCL2
  • Cytokines
  • Interleukin-1
  • Pyrimidines
  • Thiazoles
  • Thiazolidinediones
  • Tumor Necrosis Factor-alpha
  • pirinixic acid
  • 2,4-thiazolidinedione